American medicine has roughly 40 distinct physician specialties tracked by the AMA's Physician Practice Benchmark Survey. In 2024, only 5 of those specialties remained majority-owned by physicians in private practice. Cardiology fell below 50% independent over a decade ago, primary care crossed under 50% independent before that, and oncology, gastroenterology, anesthesia, and emergency medicine have all moved heavily toward hospital employment, PE consolidation, or strategic corporate ownership. The five specialties that remain majority physician-owned per AMA 2024 data share specific structural characteristics: procedure-dominant practice, ambulatory revenue base, demographic-tailwind-driven volume growth, and operator-identity attachment to independence in the practicing physician workforce. Those characteristics correlate with consolidation resistance across the specialty universe.

Ophthalmology is the most physician-owned specialty in American medicine at 70.4% private practice, orthopedic surgery sits second at 54.0%, ENT (otolaryngology) at approximately 53.8%, and plastic surgery and urology round out the top five at high-40s to low-50s percentages. Understanding which specialties are still available to patient capital in 2026, and which aren't, matters for allocators whose time horizons extend across the next decade of American healthcare consolidation. The window for accessing physician-led specialties at early-phase entry points is closing category by category, and the specialties that remain determine where patient capital can still deploy into durable operating businesses at attractive entry economics.

The 5 Specialties That Resisted

Ophthalmology has the highest private-practice rate of any US medical specialty per AMA 2024. Roughly 40 PE-backed MSOs operate in the specialty, capturing single-digit percent of practicing ophthalmologists. Strategic corporate acquirers (Cencora, McKesson) have absorbed the retina and anterior-segment trophy platforms but don't operate at sub-$10 million transaction sizes, and approximately 4,300 solo ophthalmologists are approaching succession by 2030. Demographic tailwinds (cataract volume growing 40% over past 15 years, AMD prevalence rising significantly through 2050) support continued category expansion.

Orthopedic surgery sits second-highest in private practice rate behind ophthalmology, but orthopedic consolidation is further along in practice. 18+ PE platforms are actively consolidating the specialty, with multiple recent transactions in the $500 million to $2 billion range, and specialty-specific infrastructure requirements (ASC capability, imaging, physical therapy integration) create meaningful scale advantages. The ortho window is still open but the institutional capital flood is underway, not upcoming, and entry multiples have expanded across 2022-2025.

Otolaryngology (ENT) is structurally similar to ophthalmology at an earlier stage. Procedure-dominant, ASC-heavy, subspecialty-diversified (sinus, head/neck, otology, laryngology, pediatric ENT, facial plastics). Multiple PE platforms have formed in the specialty over the last several years, with approximately 25 PE acquisitions between 2018 and 2023, and ENT is roughly 3-4 years behind ophthalmology in its consolidation curve. Less institutional competition currently, but following a trajectory that will likely mirror ophthalmology's in coming years.

Plastic surgery sits at high-40s percent private practice per AMA 2024 data. The specialty has unique characteristics: a meaningful portion of plastic surgery revenue is cash-pay (cosmetic) rather than insurance-reimbursed, which changes the consolidation economics significantly. PE consolidation has occurred in selected sub-segments (medspa platforms, certain reconstructive practices) but the cash-pay cosmetic segment has resisted institutional consolidation more than insurance-reimbursed surgical segments.

Urology sits in the high-40s percent private practice range. Cardinal Health's $1.9 billion acquisition of Solaris from Lee Equity in August 2025 represents the strategic corporate acquisition of one of urology's largest platforms, multiple PE platforms continue operating across the specialty (US Urology Partners, Solaris, Urology America, etc.), and urology is in active institutional consolidation with strategic corporate buyers and PE platforms competing for the remaining independent practices.

Why Ophthalmology Is the Cleanest Patient-Capital Opportunity

Among the five remaining majority-physician-owned specialties, ophthalmology has specific characteristics that make it the cleanest opportunity for patient-capital deployment. Its independence rate is 16 percentage points above the second-most-independent specialty (orthopedic at 54.0%), and the fragmented ownership base provides the largest pool of practices available to patient-capital acquisition. Roughly 40 PE-backed MSOs in ophthalmology capture single-digit percent of practicing physicians, which means the remaining 90%+ of the specialty operates under physician ownership or in early-stage MSO/group structures that don't yet face significant institutional competition for acquisition.

The demographic tailwinds are exceptional. Cataract surgery volume grew 40% over the past 15 years and is projected to continue growing through 2040 driven by population aging. AMD prevalence is projected to grow from 19.83 million Americans 40+ in 2019 to 21.3 million globally by 2050, diabetic retinopathy is projected to grow from 5.5 million US cases (2005) to 16 million (2050), and glaucoma prevalence is projected to grow from 2.71 million (2011) to 7.32 million (2050). These demographic drivers support multi-decade volume growth independent of unit-price reimbursement dynamics.

Workforce identity attachment to independence is structurally strong. 81.4% of vitreoretinal fellows in 2025 surveys cited autonomy and job-security concerns as primary reasons to avoid PE-owned practices, and 78% of ophthalmology trainees said they would not consider employment at a PE-backed practice. The next generation of ophthalmology workforce is structurally aligned with physician-owned practice models, which constrains PE platform recruitment and operations. Competing buyer classes have been more eliminated in ophthalmology than in any other physician-owned specialty: hospital systems are exiting physician employment expansion at six-figure per-physician annual losses, and ophthalmology was never a hospital priority due to ambulatory revenue base mismatch with hospital inpatient economics. PE platforms in ophthalmology are mostly in stabilization, restructuring, or forced-seller mode rather than aggressive acquisition. Strategic corporate acquirers have absorbed retina (Cencora) and anterior-segment trophy platforms (McKesson) but don't operate at the practice-level transaction sizes where the long tail of opportunity sits. The competing buyer classes that absorbed dental, veterinary, and dermatology consolidation aren't structurally available to absorb the long tail of ophthalmology consolidation.

ASC ownership economics are strongest in ophthalmology among comparable specialties. Practices that own their ambulatory surgery centers capture both the physician professional fee and the ASC facility fee for procedures performed at the owned facility, and the 2025 Medicare cataract ASC facility fee is approximately $1,371, roughly 2.4x the physician professional fee. ASC ownership produces a separate revenue stream that compounds with practice ownership over time, and the combined practice-plus-ASC economics generate stronger cash flow than practice-only ownership alone.

What's Distinctive about Each Remaining Specialty

The five physician-owned specialties aren't interchangeable, and each has structural characteristics that affect patient-capital deployment economics differently. Orthopedic surgery has stronger institutional competition currently: the 18+ PE platforms operating in the specialty include multiple billion-dollar platforms with active acquisition strategies, entry multiples have expanded substantially across 2022-2025, ASC ownership economics are strong (orthopedic procedures generate substantial facility fees), and specialty-specific infrastructure requirements (imaging, physical therapy, surgical equipment) require larger capital deployment per practice than ophthalmology.

ENT (otolaryngology) sits at an earlier consolidation stage with less institutional competition. ASC economics are strong but procedure mix is more diverse than ophthalmology (sinus surgery, head and neck, otology, pediatric, facial plastics each have different economics), and demographic drivers exist (sleep medicine, allergy, hearing loss) but aren't as concentrated as ophthalmology's cataract-AMD-DR-glaucoma drivers. Plastic surgery has the cash-pay cosmetic segment that operates fundamentally differently from insurance-reimbursed practice economics; cash-pay practices have different valuation, financing, and operating characteristics, and patient-capital deployment economics in plastic surgery vary significantly between cosmetic and reconstructive sub-segments. Urology has active strategic corporate competition (Cardinal-Solaris) plus multiple PE platforms, and the specialty's drug economics (prostate cancer therapy, OAB medications, hormone therapy) create vertical integration opportunities for pharmaceutical distributors that ophthalmology mostly lacks outside of retina. Urology consolidation is structurally further along than ophthalmology.

For patient-capital allocators evaluating cross-specialty deployment opportunities, ophthalmology's combination of highest fragmentation, lowest current PE penetration, strongest demographic tailwinds, strongest workforce identity, most-eliminated competing buyers, and strongest ASC economics produces the cleanest investment thesis among the five remaining physician-owned specialties.

What This Means for Capital Deployment Timing

Five physician-owned specialties remain in American medicine, and each one is on a consolidation trajectory that will eventually shift them toward PE, strategic corporate, or hospital ownership. Orthopedic and urology are in active institutional consolidation. Plastic surgery faces cash-pay segment-specific dynamics. ENT is approximately 3-4 years behind ophthalmology in consolidation curve. Ophthalmology is in the early-operator phase with structural conditions that have constrained the typical institutional flood timeline.

The window for patient-capital deployment into ophthalmology at early-phase entry economics is open in 2026-2028, with structural conditions (PE fundraising collapse, exit environment weakness, hospital retrenchment, regulatory tightening of CPOM) that have extended the early-phase window beyond what would normally be expected. Capital deployed during this window faces less institutional competition, lower entry multiples, and stronger underlying asset characteristics than the same capital would face in any of the other four specialties currently or in ophthalmology itself once the institutional flood arrives.

Across the next decade, American physician-led specialty medicine will continue consolidating. The five specialties that remain physician-owned in 2024 will not all remain physician-owned in 2034. Capital that's positioned to participate in ophthalmology specifically, during the current early-phase window, captures the cleanest entry economics available across the remaining physician-owned specialty universe. That's the structural arithmetic of where American medicine sits in 2026. Ophthalmology is one of the last five physician-led specialties capital hasn't consolidated, the specialty where the structural conditions for patient-capital deployment are clearest, where competing buyer classes have been most eliminated, and where the underlying asset characteristics most favor the patient-capital time horizon. For capital that wants to participate in physician-led specialty ownership before the consolidation window closes, ophthalmology in 2026 represents one of the cleanest opportunities available in American healthcare.

Educational material only. Figures are illustrative and individual results vary. Images are AI-generated illustrations and do not depict actual Verdira practices, physicians, or patients. See our Disclosures.